Home > News > Octoplus and Cytimmune give anticancer drug TNF new chance
May 28th, 2003
Octoplus and Cytimmune give anticancer drug TNF new chance
Abstract:
OctoPlus and CytImmune Sciences, Inc., announced today that they have entered into a collaboration agreement to develop a novel treatment for solid cancers. The treatment's active agent is the anticancer protein, tumor necrosis factor (TNF). (see 2nd story)